NCT03200847View on ClinicalTrials.gov

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 31, 2017

Primary Completion Date

July 20, 2022

Study Completion Date

October 19, 2022

Conditions
Stage IV MelanomaStage III MelanomaAdvanced Melanoma
Interventions
DRUG

Pembrolizumab with All-Trans Retinoic Acid

All the patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 All-Trans Retinoic Acid orally for 3 days surrounding each of the first four infusions of pembrolizumab

Trial Locations (2)

80045

University of Colorado Denver, Aurora

80528

Poudre Valley Hospital, Fort Collins

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT03200847 - Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | Biotech Hunter | Biotech Hunter